Articles by Andrew Hill

1 2 3 4 5

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population

Nelson, Mark; Stellbrink, Hans-Jürgen; Podzamczer, Daniel; More

AIDS. 25(3):335-340, January 28, 2011.

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

Arribas, Jose R; Horban, Andrzej; Gerstoft, Jan; More

AIDS. 24(2):223-230, January 2010.

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

Arribas, Jose R; Horban, Andrzej; Gerstoft, Jan; More

AIDS. 24(2):223-230, January 2010.

Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients

Autar, Reshma Saskia; Wit, Ferdinand WNM; Sankote, Jongkol; More

AIDS. 21(12):1535-1539, July 31, 2007.

Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals

Phillips, Andrew N.; Miller, Veronica; Sabin, Caroline; More

AIDS. 15(18):2379-2384, December 7, 2001.

Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2...

Maguire, Michael; Gartland, Martin; Moore, Sarah; More

AIDS. 14(9):1195-1201, June 16, 2000.

1 2 3 4 5